- Home
- JD vs RVMD Comparison
JD vs RVMD Comparison
Compare JD & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JD | RVMD |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | China | United States |
| Employees | 900000 | 883 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3B | 30.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JD | RVMD |
|---|---|---|
| Price | $28.21 | $186.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $39.27 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 8.3M | 2.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.17 | N/A |
| Revenue Next Year | $6.01 | $533.02 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.51 | $34.00 |
| 52 Week High | $36.86 | $193.83 |
Technical Indicators
Market Signals| Indicator | JD | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 60.25 |
| Support Level | $28.30 | $93.39 |
| Resistance Level | $28.97 | N/A |
| Average True Range (ATR) | 0.58 | 7.11 |
| MACD | 0.41 | -0.39 |
| Stochastic Oscillator | 98.40 | 64.27 |
Price Performance
Historical ComparisonAbout JD JD.com Inc.
JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.